1. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes Featured Article: Jennifer S. ten Kulve, Dick J. Veltman, Liselotte van Bloemendaal, Frederik Barkhof, Madeleine L. Drent, Michaela Diamant, and Richard G. IJzerman Diabetes Care Volume 39: 214–221 February 2016

2. STUDY OBJECTIVE Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with reduced appetite and body weight This study investigates whether these effects could be mediated by the central nervous system (CNS) ten Kulve J.S. et al. Diabetes Care 2016;39:214–221

3. STUDY DESIGN AND METHODS Randomized crossover study was performed in obese patients with type 2 diabetes Study consisted of two periods of 12-week treatment with either liraglutide 1.8 mg or insulin glargine Effects of treatment on CNS responses were determined by viewing food pictures in the fasted condition and 30 min after a meal ten Kulve J.S. et al. Diabetes Care 2016;39:214–221

4. RESULTS Decrease in HbA 1c was larger with liraglutide than insulin glargine Body weight decreased during liraglutide versus insulin glargine Patients treated with liraglutide showed decreased responses to food pictures in insula and putamen Liraglutide enhanced the satiating effect of meal intake on responses in putamen and amygdala Differences between liraglutide and insulin glargine were not observed after 12 weeks ten Kulve J.S. et al. Diabetes Care 2016;39:214–221

9. CONCLUSIONS Liraglutide decreased CNS activation significantly only after short-term treatment ten Kulve J.S. et al. Diabetes Care 2016;39:214–221